DE60127997D1 - 1,5-benzothiazepine und ihre verwendung als antihyperlipidämika - Google Patents

1,5-benzothiazepine und ihre verwendung als antihyperlipidämika

Info

Publication number: DE60127997D1
Authority: DE; Germany
Prior art keywords: hyperlipidämika; benzothiazepine
Prior art date: 2000-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60127997T

Other languages

English (en)

Other versions

DE60127997T2 (de

Inventor

Ingemar Starke

Mikael Dahlstrom

David Blomberg

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AstraZeneca AB

Original Assignee

AstraZeneca AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-21

Filing date

2001-12-17

Publication date

2007-05-31

2000-12-21 Priority claimed from SE0004811A external-priority patent/SE0004811D0/xx

2001-05-24 Priority claimed from GB0112592A external-priority patent/GB0112592D0/en

2001-12-17 Application filed by AstraZeneca AB filed Critical AstraZeneca AB

2007-05-31 Application granted granted Critical

2007-05-31 Publication of DE60127997D1 publication Critical patent/DE60127997D1/de

2008-01-17 Publication of DE60127997T2 publication Critical patent/DE60127997T2/de

2021-12-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

DE60127997T 2000-12-21 2001-12-17 1,5-benzothiazepine und ihre verwendung als antihyperlipidämika Expired - Lifetime DE60127997T2 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
SE0004811		2000-12-21
SE0004811A SE0004811D0 (sv)	2000-12-21	2000-12-21	Chemical compounds
GB0112592		2001-05-24
GB0112592A GB0112592D0 (en)	2001-05-24	2001-05-24	Chemical compounds
PCT/GB2001/005554 WO2002050051A1 (en)	2000-12-21	2001-12-17	Chemical compounds

Publications (2)

Publication Number	Publication Date
DE60127997D1 true DE60127997D1 (de)	2007-05-31
DE60127997T2 DE60127997T2 (de)	2008-01-17

Family

ID=26246111

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60127997T Expired - Lifetime DE60127997T2 (de)	2000-12-21	2001-12-17	1,5-benzothiazepine und ihre verwendung als antihyperlipidämika

Country Status (32)

Country	Link
US (1)	US7192945B2 (de)
EP (1)	EP1345918B1 (de)
JP (2)	JP3665055B2 (de)
KR (1)	KR100882342B1 (de)
CN (1)	CN1268618C (de)
AR (1)	AR035723A1 (de)
AT (1)	ATE360008T1 (de)
AU (2)	AU2222802A (de)
BG (1)	BG66342B1 (de)
BR (1)	BRPI0116397B8 (de)
CA (1)	CA2431461C (de)
CY (1)	CY1106664T1 (de)
CZ (1)	CZ305032B6 (de)
DE (1)	DE60127997T2 (de)
DK (1)	DK1345918T3 (de)
EE (1)	EE05158B1 (de)
EG (1)	EG26979A (de)
ES (1)	ES2284587T3 (de)
HU (1)	HU229050B1 (de)
IL (2)	IL156341A0 (de)
IS (1)	IS2833B (de)
MX (1)	MXPA03005637A (de)
MY (1)	MY137508A (de)
NO (1)	NO326620B1 (de)
NZ (1)	NZ526562A (de)
PL (1)	PL219847B1 (de)
PT (1)	PT1345918E (de)
RU (1)	RU2302414C2 (de)
SA (1)	SA02220610B1 (de)
SI (1)	SI1345918T1 (de)
SK (1)	SK287059B6 (de)
WO (1)	WO2002050051A1 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0000772D0 (sv)	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
GB0121337D0 (en) *	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
MY131995A (en) *	2001-09-08	2007-09-28	Astrazeneca Ab	Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
SE0104333D0 (sv)	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
GB0201850D0 (en) *	2002-01-26	2002-03-13	Astrazeneca Ab	Therapeutic treatment
GB0209467D0 (en) *	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en)	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
CN1319938C (zh) *	2002-06-20	2007-06-06	阿斯特拉曾尼卡有限公司	治疗胰岛素抵抗的邻位取代的苯甲酸衍生物
GB0304194D0 (en) *	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
EP1689378B1 (de)	2003-12-02	2009-04-15	Schwarz Pharma Ag	Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
JP4711953B2 (ja) *	2004-02-27	2011-06-29	旭化成ファーマ株式会社	新規なベンゾチアゼピン及びベンゾチエピン化合物
EP1604655A1 (de)	2004-06-09	2005-12-14	Schwarz Pharma Ag	Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
AR057828A1 (es) *	2005-09-29	2007-12-19	Astrazeneca Ab	Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
AU2007260207B2 (en)	2006-06-15	2012-11-08	Ucb Pharma Gmbh	Pharmaceutical composition with synergistic anticonvulsant effect
BRPI0808495A2 (pt)	2007-03-08	2014-07-22	Albireo Ab	Derivados de ácido 2-substituído-3-fenilpropiônico e seu uso no tratamento de doença inflamatória intestinal
CN102316872B (zh)	2008-11-26	2016-12-21	萨蒂奥根制药公司	治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
US8349899B1 (en)	2008-12-03	2013-01-08	Arrowhead Center, Inc.	Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en)	2008-12-03	2014-07-01	Arrowhead Center, Inc.	Selective inhibitors of EG5 motors and methods of use
EP4137137A1 (de)	2010-05-26	2023-02-22	Satiogen Pharmaceuticals, Inc.	Gallensäurerecyclinghemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
CA2815749C (en)	2010-11-04	2019-12-03	Albireo Ab	Ibat inhibitors for the treatment of liver diseases
US20120114588A1 (en) *	2010-11-08	2012-05-10	Albireo Ab	Ibat inhibitors for treatment of metabolic disorders and related conditions
AU2011326873B2 (en) *	2010-11-08	2015-02-19	Albireo Ab	IBAT inhibitors for treatment of metabolic disorders and related conditions
SG190433A1 (en) *	2010-11-08	2013-06-28	Albireo Ab	A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
PT2771003T (pt)	2011-10-28	2017-07-26	Lumena Pharmaceuticals Llc	Inibidores da reciclagem de ácidos biliares para tratamento de doenças hepáticas colestáticas pediátricas
EP2770990A4 (de)	2011-10-28	2015-03-11	Lumena Pharmaceuticals Inc	Gallensäurerückflusshemmer zur behandlung von hypercholämie und cholestatischer lebererkrankung
MX2015013196A (es)	2013-03-15	2016-04-15	Lumena Pharmaceuticals Inc	Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
AU2014228850A1 (en)	2013-03-15	2015-10-29	Lumena Pharmaceuticals Llc	Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) *	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات
JP6751020B2 (ja)	2014-06-25	2020-09-02	Ｅａファーマ株式会社	固形製剤及びその着色防止又は着色低減方法
CN106573033A (zh) *	2014-06-25	2017-04-19	Ea制药株式会社	固体制剂及其稳定化方法
KR101674806B1 (ko) *	2014-10-20	2016-11-10	씨제이헬스케어 주식회사	신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
EP3012252A1 (de) *	2014-10-24	2016-04-27	Ferring BV	Kristalline Form von elobixibat
US10441604B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Oral cholestyramine formulation and use thereof
EP3413878B1 (de)	2016-02-09	2021-04-14	Albireo AB	Orale cholestyraminformulierungen und verwendung davon
JP6954926B2 (ja)	2016-02-09	2021-10-27	アルビレオ・アクチボラグ	経口コレスチラミン製剤及びその使用
US10786529B2 (en)	2016-02-09	2020-09-29	Albireo Ab	Oral cholestyramine formulation and use thereof
WO2019032027A1 (en)	2017-08-09	2019-02-14	Albireo Ab	CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
CA3071285A1 (en)	2017-08-09	2019-02-14	Albireo Ab	Cholestyramine granules, oral cholestyramine formulations and use thereof
BR112020017353A2 (pt) *	2018-03-09	2020-12-15	Elobix Ab	Processos para a preparação de um composto e de uma modificação de cristal iv de elobixibat.
US10428109B1 (en)	2018-03-09	2019-10-01	Elobix Ab	Process for the preparation of 1,5-benzothiazepine compounds
TW202015699A (zh)	2018-06-05	2020-05-01	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US10793534B2 (en)	2018-06-05	2020-10-06	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
WO2019245448A1 (en)	2018-06-20	2019-12-26	Albireo Ab	Crystal modifications of odevixibat
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10975045B2 (en)	2019-02-06	2021-04-13	Aibireo AB	Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en)	2019-02-06	2021-03-09	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
MX2021008981A (es)	2019-02-06	2021-09-08	Albireo Ab	Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
CN118834175A (zh) *	2019-02-06	2024-10-25	阿尔比里奥公司	苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
WO2020167964A1 (en)	2019-02-12	2020-08-20	Mirum Pharmaceuticals, Inc.	Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
JP7256540B2 (ja) *	2019-03-26	2023-04-12	国立大学法人東北大学	血中尿毒症物質の低減剤
US12344589B2 (en)	2019-09-09	2025-07-01	Elobix Ab	Method for producing a 1,5-benzothiazepin compound
CN114761018B (zh)	2019-12-04	2025-12-02	阿尔比里奥公司	苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN114786772B (zh)	2019-12-04	2024-04-09	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN114761080B (zh)	2019-12-04	2024-07-23	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2021110887A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
AR120676A1 (es)	2019-12-04	2022-03-09	Albireo Ab	Compuestos de benzoti(di)azepina y su uso como ácido biliar
BR112022010505A2 (pt)	2019-12-04	2022-09-06	Albireo Ab	Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
WO2021110884A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
AR120679A1 (es)	2019-12-04	2022-03-09	Albireo Ab	Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
CA3158175A1 (en) *	2019-12-04	2021-06-10	Per-Goran Gillberg	Benzothiazepine compounds and their use as bile acid modulators
US11014898B1 (en)	2020-12-04	2021-05-25	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
TWI877263B (zh)	2019-12-04	2025-03-21	瑞典商艾爾比瑞歐公司	苯并噻二氮呯化合物及其作為膽酸調節劑之用途
CA3186857A1 (en)	2020-08-03	2022-02-10	Per-Goran Gillberg	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en)	2020-08-03	2022-02-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022101379A1 (en)	2020-11-12	2022-05-19	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
JP2023549226A (ja)	2020-11-12	2023-11-22	アルビレオエービー	進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット
WO2022117778A1 (en)	2020-12-04	2022-06-09	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) *	2021-06-03	2023-04-01	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2023164179A1 (en) *	2022-02-25	2023-08-31	Assembly Biosciences, Inc.	Benzothia(dia)zepine compounds for treatment of hbv and hdv
JP2025516153A (ja)	2022-04-22	2025-05-27	アルビレオ・アクチボラグ	Ａｓｂｔ阻害剤の皮下投与
CN119343140A (zh)	2022-06-09	2025-01-21	阿尔比里奥公司	治疗肝炎
AU2023304672A1 (en)	2022-07-05	2025-01-02	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
KR20250040737A (ko) *	2022-08-02	2025-03-24	상하이 하오위안 케멕스프레스 컴퍼니, 리미티드	엘로빅시바트의 결정형 ii 및 이의 제조 방법
US20240173333A1 (en)	2022-11-03	2024-05-30	Albireo Ab	Treating Alagille Syndrome (ALGS)
US20240207286A1 (en)	2022-12-09	2024-06-27	Albireo Ab	Asbt inhibitors in the treatment of renal diseases
WO2025093760A1 (en)	2023-11-03	2025-05-08	Albireo Ab	Treating pfic2 with odevixibat
WO2025146508A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4900757A (en)	1988-12-08	1990-02-13	Merrell Dow Pharmaceuticals Inc.	Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
JPH05186357A (ja)	1991-12-31	1993-07-27	Shigeo Ochi	飲食物消化分解産物吸収抑制手段
GB9203347D0 (en)	1992-02-17	1992-04-01	Wellcome Found	Hypolipidaemic compounds
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en)	1993-02-15	1995-08-14	Wellcome Found	Hypolipidaemic compounds
ZA956647B (en)	1994-08-10	1997-02-10	Wellcome Found	Hypolipidaemic compounds.
CN1084741C (zh)	1994-09-13	2002-05-15	孟山都公司	具有回肠胆汁酸转运和牛磺胆酸盐摄入抑制剂作用的新的苯并硫杂䓬
US5994391A (en)	1994-09-13	1999-11-30	G.D. Searle And Company	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9423172D0 (en) *	1994-11-17	1995-01-04	Wellcom Foundation The Limited	Hypolipidemic benzothiazepines
CN1515567A (zh)	1996-03-11	2004-07-28	G.D.ɪ��˾	具有作为回肠胆汁酸转运和牛磺胆酸盐吸收抑制剂活性的新的苯并噻庚因
GB9704208D0 (en)	1997-02-28	1997-04-16	Glaxo Group Ltd	Chemical compounds
MXPA99008417A (es)	1997-03-11	2005-02-03	Searle & Co	Terapia de combinacion que emplaza benzotiepinas inhibidoras de transporte de acido biliar ileal e inhibidores de hmg co-a reductasa.
DK0864582T3 (da)	1997-03-14	2003-09-29	Aventis Pharma Gmbh	Hypolidemiske 1,4-benzothiazepin-1,1-dioxider
AUPO763197A0 (en)	1997-06-30	1997-07-24	Sigma Pharmaceuticals Pty Ltd	Health supplement
EP1042314B1 (de)	1997-12-19	2003-03-19	G.D. Searle & Co.	Verfahren zu herstellung von enantiomerisch-anreicherte tetrahydrobenzothiepin oxyden
GB9800428D0 (en)	1998-01-10	1998-03-04	Glaxo Group Ltd	Chemical compounds
DE19825804C2 (de)	1998-06-10	2000-08-24	Aventis Pharma Gmbh	1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EA005815B1 (ru)	1998-12-23	2005-06-30	Джи.Ди.Сирл Ллс	Комбинация ингибиторов транспорта желчных кислот в подвздошной кишке и ингибиторов белка, переносящего эфиры холестерина, для сердечно-сосудистых показаний
EP1354604A1 (de)	1998-12-23	2003-10-22	G.D. Searle LLC.	Kombinationen für kardiovaskuläre Indikationen
ATE228012T1 (de)	1998-12-23	2002-12-15	Searle Llc	Kombinationen von ileumgallensäuretransports inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
KR20010102964A (ko)	1998-12-23	2001-11-17	윌리암스 로저 에이	심장혈관 징후를 위한 회장 담즙산 수송 억제인자 및피브린산 유도체의 조합물
AU776952B2 (en)	1998-12-23	2004-09-30	G.D. Searle Llc	Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
CN1195748C (zh)	1999-02-12	2005-04-06	G.D.瑟尔有限公司	具有作为回肠胆汁酸转运和牛磺胆酸摄取抑制剂活性的新的1,2－苯并硫氮杂
DE19916108C1 (de)	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv)	1999-04-19	1999-04-19	Astra Ab	New pharmaceutical foromaulations
US6287609B1 (en) *	1999-06-09	2001-09-11	Wisconsin Alumni Research Foundation	Unfermented gel fraction from psyllium seed husks
EP1259494A4 (de)	2000-02-18	2004-09-15	Merck & Co Inc	Aryloxyessigsäuren für diabetes und lipid-erkrankungen
SE0000772D0 (sv) *	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
US20020061888A1 (en)	2000-03-10	2002-05-23	Keller Bradley T.	Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6586434B2 (en)	2000-03-10	2003-07-01	G.D. Searle, Llc	Method for the preparation of tetrahydrobenzothiepines
US20020183307A1 (en)	2000-07-26	2002-12-05	Tremont Samuel J.	Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv)	2000-10-18	2000-10-18	Astrazeneca Ab	Novel formulation
WO2002053548A1 (fr)	2000-12-27	2002-07-11	Banyu Pharmaceutical Co.,Ltd.	Derives de la benzothiazepine
GB0121337D0 (en)	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
MY131995A (en)	2001-09-08	2007-09-28	Astrazeneca Ab	Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
GB0201850D0 (en)	2002-01-26	2002-03-13	Astrazeneca Ab	Therapeutic treatment
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en)	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
GB0216321D0 (en)	2002-07-13	2002-08-21	Astrazeneca Ab	Therapeutic treatment
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use

2001
- 2001-12-13 EG EG2001121345A patent/EG26979A/xx active
- 2001-12-17 DE DE60127997T patent/DE60127997T2/de not_active Expired - Lifetime
- 2001-12-17 MX MXPA03005637A patent/MXPA03005637A/es active IP Right Grant
- 2001-12-17 PL PL363380A patent/PL219847B1/pl unknown
- 2001-12-17 NZ NZ526562A patent/NZ526562A/en not_active IP Right Cessation
- 2001-12-17 IL IL15634101A patent/IL156341A0/xx unknown
- 2001-12-17 CN CNB018210317A patent/CN1268618C/zh not_active Expired - Lifetime
- 2001-12-17 EE EEP200300307A patent/EE05158B1/xx not_active IP Right Cessation
- 2001-12-17 US US10/451,262 patent/US7192945B2/en not_active Expired - Lifetime
- 2001-12-17 AU AU2222802A patent/AU2222802A/xx active Pending
- 2001-12-17 JP JP2002551548A patent/JP3665055B2/ja not_active Expired - Lifetime
- 2001-12-17 WO PCT/GB2001/005554 patent/WO2002050051A1/en not_active Ceased
- 2001-12-17 RU RU2003122205/04A patent/RU2302414C2/ru active
- 2001-12-17 KR KR1020037008425A patent/KR100882342B1/ko not_active Expired - Lifetime
- 2001-12-17 AT AT01271366T patent/ATE360008T1/de active
- 2001-12-17 SI SI200130737T patent/SI1345918T1/sl unknown
- 2001-12-17 PT PT01271366T patent/PT1345918E/pt unknown
- 2001-12-17 BR BRPI0116397A patent/BRPI0116397B8/pt not_active IP Right Cessation
- 2001-12-17 AU AU2002222228A patent/AU2002222228B2/en not_active Expired
- 2001-12-17 SK SK776-2003A patent/SK287059B6/sk not_active IP Right Cessation
- 2001-12-17 DK DK01271366T patent/DK1345918T3/da active
- 2001-12-17 CA CA2431461A patent/CA2431461C/en not_active Expired - Lifetime
- 2001-12-17 HU HU0301953A patent/HU229050B1/hu not_active IP Right Cessation
- 2001-12-17 CZ CZ2003-1717A patent/CZ305032B6/cs not_active IP Right Cessation
- 2001-12-17 EP EP01271366A patent/EP1345918B1/de not_active Expired - Lifetime
- 2001-12-17 ES ES01271366T patent/ES2284587T3/es not_active Expired - Lifetime
- 2001-12-19 MY MYPI20015774A patent/MY137508A/en unknown
- 2001-12-21 AR ARP010106011A patent/AR035723A1/es not_active Application Discontinuation
2002
- 2002-01-01 SA SA02220610A patent/SA02220610B1/ar unknown
2003
- 2003-06-08 IL IL156341A patent/IL156341A/en active IP Right Grant
- 2003-06-18 IS IS6852A patent/IS2833B/is unknown
- 2003-06-19 BG BG107928A patent/BG66342B1/bg unknown
- 2003-06-20 NO NO20032829A patent/NO326620B1/no not_active IP Right Cessation
2004
- 2004-02-16 JP JP2004038960A patent/JP2004196815A/ja active Pending
2007
- 2007-06-20 CY CY20071100808T patent/CY1106664T1/el unknown

Also Published As

Publication number	Publication date
PL219847B1 (pl)	2015-07-31
BG66342B1 (bg)	2013-07-31
HU229050B1 (en)	2013-07-29
ATE360008T1 (de)	2007-05-15
BR0116397A (pt)	2003-11-11
KR100882342B1 (ko)	2009-02-12
SI1345918T1 (sl)	2007-10-31
EG26979A (en)	2015-03-01
ES2284587T3 (es)	2007-11-16
CN1481373A (zh)	2004-03-10
AR035723A1 (es)	2004-07-07
SK7762003A3 (en)	2004-01-08
AU2222802A (en)	2002-07-01
EP1345918B1 (de)	2007-04-18
JP3665055B2 (ja)	2005-06-29
CZ305032B6 (cs)	2015-04-08
PL363380A1 (en)	2004-11-15
DE60127997T2 (de)	2008-01-17
NO326620B1 (no)	2009-01-19
IS6852A (is)	2003-06-18
EP1345918A1 (de)	2003-09-24
NO20032829D0 (no)	2003-06-20
IS2833B (is)	2013-05-15
IL156341A (en)	2009-09-22
IL156341A0 (en)	2004-01-04
SA02220610B1 (ar)	2008-03-08
MXPA03005637A (es)	2003-10-06
US7192945B2 (en)	2007-03-20
SK287059B6 (sk)	2009-10-07
BRPI0116397B1 (pt)	2015-07-21
HK1056732A1 (en)	2004-02-27
CA2431461C (en)	2011-02-08
KR20030072572A (ko)	2003-09-15
CA2431461A1 (en)	2002-06-27
PT1345918E (pt)	2007-06-27
CN1268618C (zh)	2006-08-09
JP2004196815A (ja)	2004-07-15
EE200300307A (et)	2003-10-15
DK1345918T3 (da)	2007-07-16
US20040067933A1 (en)	2004-04-08
BRPI0116397B8 (pt)	2021-05-25
MY137508A (en)	2009-02-27
NO20032829L (no)	2003-08-15
JP2004516285A (ja)	2004-06-03
RU2302414C2 (ru)	2007-07-10
CZ20031717A3 (cs)	2003-09-17
NZ526562A (en)	2005-01-28
BG107928A (bg)	2004-08-31
HUP0301953A2 (hu)	2003-10-28
WO2002050051A1 (en)	2002-06-27
EE05158B1 (et)	2009-04-15
CY1106664T1 (el)	2012-05-23
AU2002222228B2 (en)	2007-06-07

Publication	Publication Date	Title
DE60127997D1 (de)	2007-05-31	1,5-benzothiazepine und ihre verwendung als antihyperlipidämika
DE60036803D1 (de)	2007-11-29	Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE50213336D1 (de)	2009-04-16	Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung
DE50207849D1 (de)	2006-09-28	Substituierte 2-oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung
DE60127233D1 (de)	2007-04-26	4-aminopicolinate und ihre verwendung als herbizide
DE60121609D1 (de)	2006-08-31	Modifiziertes polyolefinharz, modifizierte polyolefinharzzusammensetzung und ihre verwendung
DE60234376D1 (de)	2009-12-24	3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimin-nucleoside und ihre verwendung
ATE280163T1 (de)	2004-11-15	Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
DE60131971D1 (de)	2008-01-31	1,3,8-TRIAZA-SPIROi4,5 DECAN-4-ONDERIVATIVE ALS NEUROKININREZEPTORANTAGONISTEN
ATE332294T1 (de)	2006-07-15	Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
DE50112013D1 (de)	2007-03-22	Deodorantien und antiperspirantien
DE69929983D1 (de)	2006-04-27	Trifluoromethylpyrrolcarboxamide und ihre anwendung als fungizide
DE60027479D1 (de)	2006-05-24	Harzstruktur und ihre verwendung
DE60016326D1 (de)	2005-01-05	Wasser-absorbierende Zusammensetzung und ihre Verwendung
DE50111690D1 (de)	2007-02-01	2-acyl-indolderivate und deren verwendung als antitumormittel
DE60112635D1 (de)	2005-09-22	Ölzusammensetzung und ihre Verwendung
DE60027927D1 (de)	2006-06-14	Harzstruktur und ihre verwendung
ATE419248T1 (de)	2009-01-15	Phenylsubstituierte 4-hydroxy-tetrahydropyridone und ihre verwendung als schädlingsbekämpungsmittel und herbizide
DE50008549D1 (de)	2004-12-09	Triazolotriazinone und ihre verwendung
ATE316087T1 (de)	2006-02-15	Isothiazol-derivate und ihre verwendung als schädlingsbekämpfungsmittel
DE60141871D1 (de)	2010-06-02	Oligonukleotidmarkierungsstoffe und ihre Verwendung
ATE268327T1 (de)	2004-06-15	Benzazol-verbindungen und ihre verwendung
DE50004274D1 (de)	2003-12-04	Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one und ihre verwendung als lipase-hemmer
DE59906907D1 (de)	2003-10-09	Phosphororganische verbindungen und ihre verwendung
DE50313185D1 (de)	2010-11-25	2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva

Legal Events

Date	Code	Title	Description
2008-05-08	8364	No opposition during term of opposition